Vaxcyte, Inc.(PCVX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PCVX Vaxcyte, Inc.

Post-Mkt 06-10 16:06:40 EDT

45.42

-1.46

-3.11%

盘后45.42

+0.000.00%

16:04 EDT

High47.77	Low45.31	Vol1.03M
Open46.80	D1 Closing46.88	Amplitude5.25%
Mkt Cap6.54B	Tradable Cap5.31B	Total Shares144.00M
T/O47.11M	T/O Rate0.88%	Tradable Shares116.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PCVX","market":"US","secType":"STK","nameCN":"Vaxcyte, Inc.","latestPrice":45.42,"timestamp":1781121600000,"preClose":46.88,"halted":0,"volume":1026802,"hourTrading":{"tag":"盘后","latestPrice":45.42,"preClose":45.42,"latestTime":"16:04 EDT","volume":34643,"amount":1573485.06,"timestamp":1781121888456,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.031143344709897627,"floatShares":116968635,"shares":144000000,"eps":-6.906802,"marketStatus":"Post-Mkt","change":-1.46,"latestTime":"06-10 16:06:40 EDT","open":46.8,"high":47.77,"low":45.31,"amount":47106780.17836,"amplitude":0.052474,"askPrice":46.31,"askSize":43,"bidPrice":45.1,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-6.906802,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1781136000000},"marketStatusCode":4,"adr":0,"listingDate":1591934400000,"exchange":"NASDAQ","adjPreClose":46.88,"preHourTrading":{"tag":"盘前","latestPrice":46.9,"preClose":46.88,"latestTime":"09:29 EDT","volume":564,"amount":27045.1818,"timestamp":1781098187068,"change":0.02,"changeRate":0.000427,"amplitude":0.064633},"postHourTrading":{"tag":"盘后","latestPrice":45.42,"preClose":45.42,"latestTime":"16:04 EDT","volume":34643,"amount":1573485.06,"timestamp":1781121888456,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.78888,"impliedVol":0.5597,"impliedVolPercentile":0.3944},"requestUrl":"/m/hq/s/PCVX/wiki","defaultTab":"wiki","newsList":[{"id":"2641177964","title":"Vaxcyte (PCVX) Valuation Check As VAX A1 Begins Phase 1 Group A Strep Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2641177964","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641177964?lang=en_us&edition=fundamental","pubTime":"2026-06-08 09:21","pubTimestamp":1780881700,"startTime":"0","endTime":"0","summary":"Vaxcyte (PCVX) has dosed the first participant in its Phase 1 trial of VAX-A1, a Group A Strep vaccine candidate. This is a key early step in testing a product aimed at a large unmet medical need.\nSee our latest analysis for Vaxcyte.\nDespite the positive development for VAX-A1, recent share price momentum has been soft, with the stock down 10.66% on a 30 day share price return and 20.16% on a 90 day share price return, while the 1 year total shareholder return of 28.03% and 5 year total...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-valuation-check-as-vax-a1-begins-phase-1-group","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-valuation-check-as-vax-a1-begins-phase-1-group","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","PCVX","IE0009354923.USD","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640184492","title":"Vaxcyte COO Jim Wassil disposes of common shares worth $111,467.81","url":"https://stock-news.laohu8.com/highlight/detail?id=2640184492","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640184492?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:59","pubTimestamp":1780520387,"startTime":"0","endTime":"0","summary":"Vaxcyte COO Jim Wassil sold 2,250 common shares on June 1, 2026.Sales were executed at weighted-average prices of $49.4 and $50.26.Wassil’s direct holding fell to 158,494 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL5KJ05X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vaxcyte COO Jim Wassil disposes of common shares worth $111,467.81","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","PCVX","BK4139","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640186410","title":"Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640186410","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640186410?lang=en_us&edition=fundamental","pubTime":"2026-06-04 02:00","pubTimestamp":1780509641,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-repligen-rgen-vaxcyte-pcvx-and-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-repligen-rgen-vaxcyte-pcvx-and-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO","BK4121","LU0106261612.USD","RGEN","BK4526","LABU","LU0053671581.USD","LU1815336091.USD","BK4139","BK4137","LU0128526141.USD","LU0029874061.USD","LU0012050646.USD","XLV","BK4581","PCVX","ONC","HCSG","IE0009354923.USD","XBI","BK4585","LU0757428866.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640924156","title":"Vaxcyte (PCVX) Has a New Rating from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2640924156","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640924156?lang=en_us&edition=fundamental","pubTime":"2026-06-03 08:16","pubTimestamp":1780445774,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Salim Syed initiated coverage with a Buy rating on Vaxcyte yesterday and set a price target of $163.00. According to TipR...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vaxcyte-pcvx-has-a-new-rating-from-mizuho-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vaxcyte-pcvx-has-a-new-rating-from-mizuho-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640068925","title":"Vaxcyte doses first participant in VAX-A1 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2640068925","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640068925?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:28","pubTimestamp":1780432135,"startTime":"0","endTime":"0","summary":"Vaxcyte (PCVX) announced that the first participant was dosed in the Phase 1, first-in-human study evaluating VAX-A1, the company’s investigational...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vaxcyte-doses-first-participant-in-vax-a1-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vaxcyte-doses-first-participant-in-vax-a1-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PCVX","LU0053671581.USD","IE0009354923.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640253869","title":"Vaxcyte publishes investor presentation highlighting broad-spectrum pneumococcal vaccine pipeline lead VAX-31","url":"https://stock-news.laohu8.com/highlight/detail?id=2640253869","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640253869?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:17","pubTimestamp":1780431456,"startTime":"0","endTime":"0","summary":"Vaxcyte highlighted completed enrollment in OPUS-1, a Phase 3 noninferiority trial for VAX-31 in U.S. adults aged 50 and older.Topline OPUS-1 safety, tolerability, immunogenicity data targeted for Q4 2026; OPUS-2 and OPUS-3 readouts targeted for H1 2027.VAX-31 holds FDA Breakthrough Therapy designation for invasive pneumococcal disease, pneumonia; designed to cover about 95% of IPD in adults.Cash, cash equivalents, investments totaled about $2.7 billion as of 3/31/26.Manufacturing strategy includes a global commercial agreement with Lonza; separate Thermo Fisher deal for U.S. fill-finish capacity in North Carolina.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL2RfvRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1633808545.USD","IE00BJJMRZ35.SGD","PCVX","LU1548497426.USD","LU2543165471.USD","BK4566","IE00B19Z8W00.USD","LU2125909916.SGD","IE00B19Z9505.USD","IE00BQXX3D17.EUR","BK4588","LU2125909759.SGD","LU2433249047.HKD","LU0096362180.USD","LU2360108059.USD","LU1670627923.USD","LU2089984988.USD","BK4534","LU0061474960.USD","LU2125909593.SGD","LU1153585028.USD","BK4121","LU2063271972.USD","LU2764263203.CNY","LU1988902786.USD","IE00B1BXHZ80.USD","LU1064131342.USD","LU0957791311.USD","IE0034235188.USD","LU0432979614.USD","LU2125910179.SGD","IE0009354923.USD","TMO","BK4548","LU0823416689.USD","BK4533","BK4585","LU1280957306.USD","GB00BDT5M118.USD","LU1623119135.USD","IE00B4R5TH58.HKD","LU0345770993.USD","IE00B19Z8X17.USD","LU1291159041.SGD","LU1791710582.SGD","LU2298321311.HKD","LU1923622614.USD","LU1712237335.SGD","LU2720916845.USD","LU2357305700.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640923498","title":"Vaxcyte - Expects Topline Data From Vax-a1 Phase 1 Study in H2 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2640923498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640923498?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:05","pubTimestamp":1780430701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA3C03JL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PCVX","LU0053671581.USD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640892345","title":"Vaxcyte Doses First Participant in Phase 1 Study Evaluating Vax-a1 for the Prevention of Disease Caused by Group a Streptococcus in Healthy Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2640892345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640892345?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:05","pubTimestamp":1780430701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA3C03JL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IE0009354923.USD","LU0053671581.USD","PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638519212","title":"S&P 500 Futures Climb In Premarket Trading; MDA Space, ViaSat Lead","url":"https://stock-news.laohu8.com/highlight/detail?id=2638519212","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638519212?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:30","pubTimestamp":1779795000,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, MDA Space Ltd.  was up 17.8% in pre-market trading, and ViaSat Inc.  was up 15.7%.Modine Manufacturing Co. , Vaxcyte Inc. , and Intuitive Machines Inc. Cl A  were all posting gains of at least 11%. In early trading, AutoZone Inc.  and CGI Inc. Cl A  had posted declines, falling 5.6% and 4.1%, respectively.Meanwhile S&P 500 futures were up 0.68%, with futures for the Dow Jones Industrial Average rising 0.59%. The Cboe Volatility Index futures were up 1.29%.In commodities news, Brent crude oil futures were up 2.46%, and gold futures were up 0.15%. Bitcoin fell 0.29% to $77,163.In the previous regular trading session, the S&P 500 and the Dow were up 0.37% and 0.58%, respectively. Stocks in Asia were down overnight, with Japan's NIKKEI 225 Index down 0.25% and China's Shanghai Composite Index falling 0.17%.U.S. stock markets open for trading at ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MMAX","BK4124","SCHX","BK4602","GIB","SPLV","SPMO","GPIX","LU1221951046.USD","JEPI","DMAX","LU1221951129.SGD","LU1037948541.HKD","IE0009354923.USD","LU0345770308.USD","SPYD","SMAX","SPYV","IVV","LU1032955483.USD","LU1037948897.HKD","SSO","SPXU","LU1506573853.SGD","SPHD","ETFT","BK4585","LU1934455863.HKD","LU1934455194.USD","BK4214","GSLC","IE00B19Z4B17.USD","RSP","LU1571399168.USD","IE0031619046.USD","MOAT","XLG","IVE","MOD","HIBS","BK4511","SDS","XDTE","UPRO","IVW","VBK","LU2463526074.USD","LUNR","VV","LU0053666078.USD","DBSC","ITOT","SPYG","LU0053671581.USD","SPYH","ACWI","LU0861579265.USD","LU2065731478.USD","RSPN","SPGP","LU0965509101.SGD","SPUS","BMAY","HIBL","BK4020","BK4588","SH","VXX","SPXL","SPUU","SPYM","PCVX","AZO","LU0234570918.USD","ALLW","BK4134","LU0965508806.USD","LUNL","TSPY","RSPU","IE00B66KJ199.SGD","SPXS","SPHQ","VSAT","VTI","SPYQ","SPDN","LU1196500208.SGD","BK4187","IJH","VTV","SPYU","VEU","SFY","BK4086","LU0965509010.AUD","LU0965509283.SGD","IE00B7SZL793.SGD",".SPX","IJR","XYLD","BK4139","YSPY","LU1934455277.USD","LU0314106906.USD","NOBL","MDALF","SCHB","RSPA","LU0345770993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633091178","title":"Vaxcyte Down Over 10%, On Track for Largest Percent Decrease Since May 2025 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2633091178","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633091178?lang=en_us&edition=fundamental","pubTime":"2026-05-08 03:03","pubTimestamp":1778180580,"startTime":"0","endTime":"0","summary":"Vaxcyte, Inc.  is currently at $51.12, down $5.98 or 10.47%. --Would be lowest close since Jan. 21, 2026, when it closed at $50.22. --On pace for largest percent decrease since May 6, 2025, when it fell 14.7%. --Down 56.65% from its all-time closing high of $117.93 on Oct. 16, 2024. --Up 62.54% from 52 weeks ago , when it closed at $31.45. --Up 73.76% from its 52-week closing low of $29.42 on May 14, 2025. --Traded as low as $48.49; lowest intraday level since Jan. 21, 2026, when it hit $46.92. --Down 15.08% at today's intraday low; largest intraday percent decrease since April 1, 2025, when it fell as much as 15.82%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","BK4139","IE0009354923.USD","PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633812721","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Evotec AG (EVO), Vaxcyte (PCVX) and ACADIA Pharmaceuticals (ACAD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633812721","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633812721?lang=en_us&edition=fundamental","pubTime":"2026-05-08 01:40","pubTimestamp":1778175631,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Evotec AG (EVO), Vaxcyte (PCVX) and ACADIA Pharmac...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-evotec-ag-evo-vaxcyte-pcvx-and-acadia-pharmaceuticals-acad-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-evotec-ag-evo-vaxcyte-pcvx-and-acadia-pharmaceuticals-acad-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","BK4139","EVO","LU0128526141.USD","XBI","LU0029874061.USD","XLV","ACAD","IE0009354923.USD","LU2065171311.SGD","BK4137","LU2065170008.USD","HCSG","BK4585","BK4581","LU2065171402.SGD","LU0053671581.USD","PCVX","BK4210","LU2065169927.USD","BK4121","AG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633227157","title":"Vaxcyte Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633227157","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633227157?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:49","pubTimestamp":1778100565,"startTime":"0","endTime":"0","summary":"Vaxcyte Inc reports results for the quarter ended December 31 - Earnings SummaryVaxcyte Inc PCVX.OQ reported a quarterly adjusted loss of $1.80 per share for the quarter ended December 31, lower than ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL8N41J3IE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX","LU0053671581.USD","IE0009354923.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633152082","title":"Vaxcyte Q1 EPS $(2.30) Misses $(1.82) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633152082","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633152082?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:35","pubTimestamp":1778099740,"startTime":"0","endTime":"0","summary":"Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(2.30) per share which missed the analyst consensus estimate of $(1.82) by 26.37 percent. This is a 121.15 percent decrease over losses of $(1.04) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52346535/vaxcyte-q1-eps-2-30-misses-1-82-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vaxcyte Q1 EPS $(2.30) Misses $(1.82) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633115423","title":"Vaxcyte Q1 net loss widens to $320.6 million; R&D expenses jump to $312.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633115423","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633115423?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:20","pubTimestamp":1778098808,"startTime":"0","endTime":"0","summary":"Vaxcyte posted a net loss of USD 320.6 million for first-quarter 2026, widening from USD 140.7 million a year earlier, while R&D expense more than doubled to USD 312.8 million.Cash, cash equivalents and investments rose to USD 2.74 billion as of March 31, 2026 from USD 2.44 billion at year-end 2025, including USD 601.8 million in net proceeds from a February equity offering.Enrollment is now complete across OPUS-1, OPUS-2 and OPUS-3 Phase 3 adult trials of VAX-31, with 6,191 adults dosed; OPUS-1 topline safety, tolerability and immunogenicity data are expected in fourth-quarter 2026.Management said it remains on track for planned BLA submission and potential U.S. commercial launch, with a Phase 1 adult study for Group A Strep candidate VAX-A1 slated to start in mid-2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL2WVk0J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2210149790.SGD","SG9999014013.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4112","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2095319765.USD","BK4139","IE00BN0W2T93.GBP","SG9999014039.USD","IE00B64PRP62.GBP","IE0009354923.USD","LU0053671581.USD","SG9999014005.SGD","NDAQ","BK4588","SG9999014021.USD","PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633937151","title":"BRIEF-Vaxcyte Q1 Operating Expenses USD 345.85 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633937151","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633937151?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:05","pubTimestamp":1778097946,"startTime":"0","endTime":"0","summary":"BRIEF-Vaxcyte Q1 Operating Expenses USD 345.85 Million\n\n\nMay 06 (Reuters) - Vaxcyte Q1 net income USD -320.622 million vs. IBES estimate USD -256.4 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLXDEBE82:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PCVX","IE0009354923.USD","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632628470","title":"Vaxcyte COO Jim Wassil disposes of USD 127,869 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2632628470","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632628470?lang=en_us&edition=fundamental","pubTime":"2026-05-02 05:38","pubTimestamp":1777671524,"startTime":"0","endTime":"0","summary":"Vaxcyte Chief Operating Officer Jim Wassil sold 2,250 common shares on May 1, 2026.Sale priced at USD 56.83 per share on weighted-average basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL5gVlfS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vaxcyte COO Jim Wassil disposes of USD 127,869 common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE0009354923.USD","LU0053671581.USD","PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629683718","title":"Vaxcyte announces upcoming annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629683718","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629683718?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:11","pubTimestamp":1776975064,"startTime":"0","endTime":"0","summary":"Vaxcyte schedules virtual annual stockholder meeting for June 15, 2026.Stockholders will vote to elect three Class III directors to serve until 2029.Meeting agenda includes ratification of Deloitte & Touche as independent registered public accounting firm for fiscal 2026.Advisory vote planned on compensation for named executive officers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL6yv2r2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX","LU0053671581.USD","IE0009354923.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627285686","title":"Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Merit Medical Systems (MMSI) and Vaxcyte (PCVX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2627285686","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627285686?lang=en_us&edition=fundamental","pubTime":"2026-04-15 18:40","pubTimestamp":1776249615,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rocket Pharmaceuticals (RCKT), Merit Medical Systems (MMSI) and V...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-rocket-pharmaceuticals-rckt-merit-medical-systems-mmsi-and-vaxcyte-pcvx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-rocket-pharmaceuticals-rckt-merit-medical-systems-mmsi-and-vaxcyte-pcvx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0053671581.USD","LU1559883803.SGD","BK4581","BK4588","XBI","MMSI","XLV","LU0029874061.USD","IE0009354923.USD","PCVX","BK4198","LU0566484027.USD","BK4139","LU0128526141.USD","RCKT","HCSG","BK4137","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626922799","title":"Vaxcyte SVP Finance Elvia Cowan disposes of USD 180,000 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2626922799","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626922799?lang=en_us&edition=fundamental","pubTime":"2026-04-09 04:33","pubTimestamp":1775680405,"startTime":"0","endTime":"0","summary":"Vaxcyte SVP, Finance & CAO Elvia Cowan sold 3,000 shares on April 7 at USD 60.She exercised options for 3,000 shares on April 7 at USD 25.92.Directly held common stock position stood at 28,975 shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDLbVTVkN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vaxcyte SVP Finance Elvia Cowan disposes of USD 180,000 common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","PCVX","LU0053671581.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625696516","title":"Vaxcyte to present at Needham Virtual Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2625696516","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625696516?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:06","pubTimestamp":1775592391,"startTime":"0","endTime":"0","summary":"Vaxcyte management will join a fireside chat at Needham 25th Annual Virtual Healthcare Conference on April 14, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL7B3RCL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4139","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","NDAQ","SG9999014039.USD","LU2210150020.SGD","LU2095319765.USD","LU0053671581.USD","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4585","SG9999014021.USD","LU2210149790.SGD","PCVX","IE00BN0W2W23.USD","BK4588","IE0009354923.USD","BK4112","SG9999014005.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vaxcyte.com","stockEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":-0.1156},{"period":"3month","weight":-0.1851},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.2602},{"period":"ytd","weight":0.016}],"compareEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.0898},{"period":"6month","weight":0.0695},{"period":"1year","weight":0.2291},{"period":"ytd","weight":0.0808}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.007757},{"month":2,"riseRate":0.5,"avgChangeRate":0.015611},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.13682},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.015657},{"month":5,"riseRate":0.5,"avgChangeRate":0.041128},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.004814},{"month":7,"riseRate":0.5,"avgChangeRate":0.011479},{"month":8,"riseRate":0.833333,"avgChangeRate":0.13264},{"month":9,"riseRate":0.5,"avgChangeRate":0.090313},{"month":10,"riseRate":0.333333,"avgChangeRate":0.104582},{"month":11,"riseRate":0.5,"avgChangeRate":-0.025818},{"month":12,"riseRate":0.5,"avgChangeRate":0.007817}],"exchange":"NASDAQ","name":"Vaxcyte, Inc.","nameEN":"Vaxcyte, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vaxcyte, Inc.(PCVX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vaxcyte, Inc.(PCVX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vaxcyte, Inc.,PCVX,Vaxcyte, Inc.股票,Vaxcyte, Inc.股票老虎,Vaxcyte, Inc.股票老虎国际,Vaxcyte, Inc.行情,Vaxcyte, Inc.股票行情,Vaxcyte, Inc.股价,Vaxcyte, Inc.股市,Vaxcyte, Inc.股票价格,Vaxcyte, Inc.股票交易,Vaxcyte, Inc.股票购买,Vaxcyte, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vaxcyte, Inc.(PCVX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vaxcyte, Inc.(PCVX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction